MBS659638 | Epilepsy, Progressive Myoclonus Type 2A (Lafora Disease, EPM2A, Laforin, LD, LDE, EPM2, MELF, LAFPTPase, FLJ11207, KIAA0766) (Control Peptide)

Epilepsy, Progressive Myoclonus Type 2A (Lafora Disease, EPM2A, Laforin, LD, LDE, EPM2, MELF, LAFPTPase, FLJ11207, KIAA0766) (Control Peptide) | MBS659638 | MyBiosource

Product Short Name: [Epilepsy, Progressive Myoclonus Type 2A]

Product Name Synonyme: N/A

Other Names: [Epilepsy, progressive myoclonus type 2A, Lafora disease (laforin); Laforin; laforin; LAFPTPase; lafora PTPase; epilepsy, progressive myoclonus type 2, Lafora disease (laforin); epilepsy, progressive myoclonus type 2A, Lafora disease (laforin); Lafora PTPase]

Product Gene Name: N/A

Product Gene Name Synonyme: N/A

Other Gene Names: [EPM2A; EPM2A; EPM2; MELF; LAFPTPase]

Clonality: N/A

Isotype: N/A

Clone: N/A

Host: N/A

Reactivity: N/A

Specificity: N/A

Purity: Highly Purified
Highly Purified

Form: Supplied as a lyophilized powder in PBS.

Concentration: N/A

Storage Stability: May be stored at 4 degree C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can

Tested Application: ELISA (EL/EIA)